Sermorelin vs CJC-1295: Comparing Two GH Secretagogues
Both nudge your own growth hormone. The difference is half-life, dosing, and how much human evidence actually exists.
Sermorelin and CJC-1295 are often discussed in the same breath, and for good reason: both are growth-hormone-releasing hormone (GHRH) analogues that prompt the pituitary to release its own growth hormone (GH) rather than introducing GH directly. That shared mechanism is where the easy similarities end. The practical differences — how long they last, how they’re dosed, and how much human evidence stands behind each — matter more than the marketing usually admits.
The mechanism they share
Both compounds bind GHRH receptors on the pituitary and stimulate a pulse of endogenous GH. In principle this is a gentler approach than injecting recombinant GH, because the body’s own feedback loops still have a say. That theoretical advantage is appealing, but “more physiological” is a mechanistic argument, not a demonstrated clinical outcome in healthy adults.
Stimulating your own GH release is biologically plausible — and not the same as proving meaningful, durable benefits in healthy people. The peer-reviewed human outcome literature here is thin.
Where they diverge
The headline difference is half-life.
| Half-life | Dosing | Human data | |
|---|---|---|---|
| Sermorelin (GHRH 1-29) | ~10–20 minutes | Frequent | Oldest regulatory history (former diagnostic/pediatric drug) |
| CJC-1295 without DAC | Short (minutes) | Frequent | Sparse outcome data |
| CJC-1295 with DAC | ~5.8–8.1 days | Weekly/biweekly | One PK study; no outcome trials in healthy adults |
The “with DAC” version is the source of most confusion. The Drug Affinity Complex covalently binds the peptide to serum albumin, extending its half-life dramatically. The figures above come from Teichman et al. (2006) in The Journal of Clinical Endocrinology & Metabolism — two randomized, double-blind, placebo-controlled trials in healthy adults that found a single CJC-1295 injection raised mean GH 2- to 10-fold for 6 days or more and IGF-1 1.5- to 3-fold for 9–11 days.
Why the duration matters
Pulsatile GH release is how healthy physiology works. A continuous, days-long elevation may not replicate the same downstream signaling — and that PK study measured hormone levels, not health outcomes. Whether the longer-acting version is better, worse, or simply different is not settled by the data we have.
What the evidence actually supports
Sermorelin has the deepest paper trail, including historical diagnostic and pediatric use. CJC-1295’s published human data is essentially a single pharmacokinetic study; claims about fat loss, recovery, or anti-aging in healthy adults run well ahead of what’s been demonstrated. Both share the realities of the category: outside approved indications, supply is unregulated, purity varies, and long-term safety in healthy people hasn’t been characterized.
The takeaway
They share a mechanism but differ in duration: sermorelin has more history, while CJC-1295’s DAC form is more theoretically aggressive and studied mainly for its hormone-elevating pharmacokinetics, not for clinical benefit. None of that adds up to a confident recommendation. The biology is interesting; the human evidence for benefit in healthy adults is not yet there.